Trial Profile

Phase 2 study of EM-221 for Tourette Syndrome

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EM 221 (Primary)
Indications Gilles de la Tourette's syndrome
Focus Therapeutic Use

Most Recent Events

30 Jul 2025 According to the EuMentis Therapeutics Media Release, EM-221 has been cleared by the U.S. FDA for Phase 2 evaluation, and the company expects to begin dosing in its first clinical trial in the second half of 2025.
13 Feb 2023 New trial record
08 Feb 2023 According to an EuMentis Therapeutics media release, the company expect to initiate this trial in H2 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com